E-viri
PDF
Recenzirano
Odprti dostop
-
Frey, Sharon E; Winokur, Patricia L; Salata, Robert A; El-Kamary, Samer S; Turley, Christine B; Walter, Emmanuel B; Hay, Christine Mhorag; Newman, Frances K; Hill, Heather R; Zhang, Ying; Chaplin, Paul; Tary-Lehmann, Magdalena; Belshe, Robert B
Vaccine, 06/2013, Letnik: 31, Številka: 29Journal Article
Highlights • Reintroduction of Variola major as an agent of bioterrorism remains a concern. • A compressed schedule of MVA was evaluated for use in a post event scenario. • MVA is well tolerated when given as two standard doses at Days 0 and 28 or 0 and 7. • A 2nd dose of MVA at Day 28 compared to Day 7 provided greater antibody responses. • INF-γ expression was greatest within 2 weeks after last vaccination.
